Skip to main content
SpringerLink
Log in

Carvedilol Exerts More Potent Antiadrenergic Effect than Metoprolol in Heart Failure

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Background: It is still uncertain whether or not there is a difference between metoprolol and carvedilol for the treatment of congestive heart failure. We attempted to determine the difference between the two β-blockers in terms of their antiadrenergic effect during exercise in patients with heart failure and their efficacy based on the baseline plasma brain natriuretic peptide concentration. Methods: Fifty-three patients with mild to moderate heart failure with a radionuclide left ventricular ejection fraction <40% received open label metoprolol or carvedilol in a randomized fashion. The increase in the heart rate normalized to the increase in the plasma norepinephrine concentration during exercise, was calculated as an index of adrenergic responsiveness during exercise. Results: The increase in heart rate normalized by the increase in plasma norepinephrine concentration, decreased after the initiation of β-blockers in the carvedilol group, but not in the metoprolol group. The change in cardiac function was more favorable for carvedilol than metoprolol in patients who exhibited a higher baseline brain natriuretic peptide concentration. Conclusions: Carvedilol exerts a more potent antiadrenergic effect than metoprolol during stress in patients with mild to moderate heart failure. Carvedilol appears to be more efficacious than metoprolol in patients who exhibit higher baseline brain natriuretic peptide concentrations. These differences should be kept in mind when selecting appropriate pharmacologic agents in the treatment of heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. The U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.

    Google Scholar 

  2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9–13.

    Google Scholar 

  3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–2007.

    Google Scholar 

  4. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.

    Google Scholar 

  5. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817–2825.

    PubMed  CAS  Google Scholar 

  6. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999;33:1926–1934.

    Article  PubMed  CAS  Google Scholar 

  7. Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522–1528.

    Article  PubMed  CAS  Google Scholar 

  8. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645–2651.

    PubMed  CAS  Google Scholar 

  9. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102:546–551.

    PubMed  CAS  Google Scholar 

  10. Maack C, Elter T, Nickenig T, et al. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J Am Coll Cardiol 2001;38:939–946.

    Article  PubMed  CAS  Google Scholar 

  11. The COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.

    Google Scholar 

  12. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17 (Suppl B):8–16.

    PubMed  CAS  Google Scholar 

  13. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 1994;45:490–499.

    PubMed  CAS  Google Scholar 

  14. Bond RA, Leff P, Johnson TD, et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature 1995;374:272–276.

    Article  PubMed  CAS  Google Scholar 

  15. Iwata M, Yoshikawa T, Baba A, et al. Autoimmunity against the second extracellular loop of β1-adrenergic receptors induces β-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 2001;88:578–586.

    PubMed  CAS  Google Scholar 

  16. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189–6193.

    PubMed  CAS  Google Scholar 

  17. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105:2867–2871.

    PubMed  CAS  Google Scholar 

  18. Yokota Y, Nomura H, Kawai H, et al. Effects of long-term beta-blockada (metoprolol) therapy in patients with dilated cardiomyopathy, Jpn Circ J 1991;55:343–355.

    PubMed  CAS  Google Scholar 

  19. The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) Investigators. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure. Am Heart J 2004;147:324–330.

    Google Scholar 

  20. Colucci WS, Ribeiro JP, Rocco MB, et al. Impaired chronotropic response to exercise in patients with congestive heart failure: role of postsynaptic beta-adrenergic desensitization. Circulation 1989;80:314–323.

    PubMed  CAS  Google Scholar 

  21. Asano K, Zisman LS, Yoshikawa T, Headley V, Bristow MR, Port JD. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. J Cardiovasc Pharmacol 2001;37:678–691.

    Article  PubMed  CAS  Google Scholar 

  22. Kindermann M, Maack C, Schaller S, et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004;109:3182–3190.

    Article  PubMed  CAS  Google Scholar 

  23. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of meta-analysis. Am Heart J 2001;141:884–907.

    Google Scholar 

  24. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509–516.

    PubMed  CAS  Google Scholar 

  25. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278–1283.

    PubMed  CAS  Google Scholar 

  26. Richards AM, Doughty R, Nichols MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction: Australia-New Zealand Heart Failure Group. Circulation 1999;99:786–792.

    PubMed  CAS  Google Scholar 

  27. Maack C, Cremers B, Flesch M, Höper A, Südkamp M, Böhm M. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 2000;130:1131–1139.

    Article  PubMed  CAS  Google Scholar 

  28. Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002;105:2429–2434.

    Article  PubMed  CAS  Google Scholar 

  29. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154–1161.

    Article  PubMed  CAS  Google Scholar 

  30. Gottlieb SS, Fisher ML, Kjekshus J, et al. Tolerability of β-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002;105:1182–1188.

    PubMed  CAS  Google Scholar 

  31. Hara Y, Hamada M, Shigematsu Y, et al. Effect of beta-blocker on LV function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 2000;64:365–369.

    Article  PubMed  CAS  Google Scholar 

  32. Fujimura M, Yasumura Y, Ishida Y, et al. Improvement in LV function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail 2000;6:3–10.

    PubMed  CAS  Google Scholar 

  33. Hirooka K, Yasumura Y, Ishida Y, et al. Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Jpn Circ J 2001;65:931–936.

    Article  PubMed  CAS  Google Scholar 

  34. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma BNP as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy. Am Heart J 2001;141:925–932.

    Article  PubMed  CAS  Google Scholar 

  35. Ohtsuka T, Hamada M, Saeki H, et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2002;89:996–999.

    Article  PubMed  CAS  Google Scholar 

  36. Fung JWH, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003;92:406–410.

    PubMed  CAS  Google Scholar 

  37. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation 2000;101:378–384.

    Google Scholar 

  38. Stanek B, Frey B, Hülsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced LV dysfunction. J Am Coll Cardiol 2001;38:436–442.

    Article  PubMed  CAS  Google Scholar 

  39. Yoshizawa A, Yoshikawa T, Nakamura I, et al. Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure. J Card Fail 2004;10:310–315.

    PubMed  CAS  Google Scholar 

  40. Bristow MR, Feldman AM, Adams KF Jr, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail 2003;9:444–453.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    Takashi Kohno, Tsutomu Yoshikawa, Akihiro Yoshizawa, Iwao Nakamura, Toshihisa Anzai, Toru Satoh & Satoshi Ogawa

  2. Cardiology Division, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Tsutomu Yoshikawa

Authors
  1. Takashi Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsutomu Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akihiro Yoshizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Iwao Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshihisa Anzai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toru Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Yoshikawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kohno, T., Yoshikawa, T., Yoshizawa, A. et al. Carvedilol Exerts More Potent Antiadrenergic Effect than Metoprolol in Heart Failure. Cardiovasc Drugs Ther 19, 347–355 (2005). https://doi.org/10.1007/s10557-005-4761-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-005-4761-9

Key Words

Search

Navigation